Genomic Landscape of Metastatic Urothelial Cancer in a Multicenter Cohort From Argentina
- 1 August 2026
- journal article
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (8)
Abstract
PURPOSE: The genomic landscape of advanced urothelial carcinoma (aUC) has enabled the development of targeted therapies; however, real-world data from Latin America remain limited. MATERIALS AND METHODS: We conducted a multicenter retrospective study including patients with aUC who underwent next-generation sequencing on tumor tissue. Molecular alterations were classified according to the European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of Molecular Targets (ESCAT). RESULTS: A total of 107 patients were included. Overall, 68 patients (63.6%) harbored at least one potentially actionable molecular alteration. Among these, 34 patients (31.8%) exhibited ESCAT level I alterations, most commonly involving FGFR3 mutations/fusions and ERBB2 amplification. CONCLUSION: A clinically meaningful proportion of Argentine patients with aUC harbor ESCAT level I actionable alterations, supporting the incorporation of routine genomic profiling into clinical practice.Keywords
This publication has 20 references indexed in Scilit:
- The genomic and transcriptomic landscape of metastastic urothelial cancerNature Communications, 2024
- The Impact of Fibroblast Growth Factor Receptor Alterations in Clinical Outcomes of Patients With Advanced Urothelial Carcinoma: Real-World Data From a Latin American PopulationClinical Genitourinary Cancer, 2024
- The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysisNature Communications, 2024
- Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial CarcinomaNew England Journal of Medicine, 2023
- Erdafitinib treatment in Brazilian patients with metastatic urothelial carcinoma (mUC): real-world evidence from an Expanded Access ProgramTherapeutic Advances in Medical Oncology, 2021
- A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)Annals of Oncology, 2018
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patientsNature Medicine, 2017
- Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterationsCancer, 2015
- The present and future burden of urinary bladder cancer in the worldWorld Journal of Urology, 2009
- Mechanisms of Disease: the epidemiology of bladder cancerNature Reviews Endocrinology, 2006